{"organizations": [], "uuid": "f0f0ad6118f334482afea75c5e0f733189cded08", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 106, "shares": 106, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.timeslive.co.za", "main_image": "", "site_section": "http://www.timeslive.co.za/?service=rss", "section_title": "TimesLIVE", "url": "http://www.timeslive.co.za/thetimes/2017/02/28/US-trial-seeks-HIV-positive-South-Africans-for-study1", "country": "ZA", "domain_rank": 7481, "title": "US trial seeks HIV-positive South Africans for study", "performance_score": 1, "site": "timeslive.co.za", "participants_count": 0, "title_full": "US trial seeks HIV-positive South Africans for study", "spam_score": 0.0, "site_type": "news", "published": "2017-02-28T14:00:00.000+02:00", "replies_count": 0, "uuid": "f0f0ad6118f334482afea75c5e0f733189cded08"}, "author": "", "url": "http://www.timeslive.co.za/thetimes/2017/02/28/US-trial-seeks-HIV-positive-South-Africans-for-study1", "ord_in_thread": 0, "title": "US trial seeks HIV-positive South Africans for study", "locations": [], "entities": {"persons": [{"name": "carl dieffenbach", "sentiment": "none"}, {"name": "dieffenbach", "sentiment": "none"}, {"name": "ramjee", "sentiment": "none"}, {"name": "gita ramjee", "sentiment": "none"}], "locations": [{"name": "us", "sentiment": "none"}, {"name": "south africa", "sentiment": "none"}], "organizations": [{"name": "national institute of allergy and infectious diseases", "sentiment": "none"}, {"name": "us national institutes of health", "sentiment": "none"}, {"name": "sa medical research council", "sentiment": "none"}, {"name": "times", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Print \nSomeone with HIV can have more than double the chance of developing heart disease and strokes as an HIV-negative person. \nThe trial, funded by the US National Institutes of Health, is recruiting HIV-positive South Africans over 40 to join Americans, Brazilians, Thais and Canadians in the research. \nAntiretrovirals offer an almost normal life expectancy to HIV-positive people, but their greater risk of lifestyle disease shortens life expectancy. \nTrial investigator Carl Dieffenbach of the National Institute of Allergy and Infectious Diseases at the US National Institutes of Health said: \"If HIV-positive people start therapy early enough [after infection] they can live a relatively normal lifestyle\". \n\"HIV is in you forever and all the therapy does is suppress it, but pieces of virus activate the immune system. \n\"Activating the immune system causes inflammation and this can increase the risk of blocked arteries and even increase cholesterol,\" Dieffenbach said. \nInitial data suggest statins, commonly used to control cholesterol and given to people at risk of heart disease, can reduce inflammation in HIV-positive people. \nThe participants, 6,500 globally, with all over 40 and under 75, have to be on antiretrovirals. \nThey will be administered a low-dose statin or a placebo to see if the statin reduces their likelihood of strokes and heart attacks. \nThe trial group will be monitored over six years. \nPeople with HIV had a \"double jeopardy\", said Gita Ramjee of the SA Medical Research Council. \n\"We want all HIV-positive people to live a good life and avoid the risk of heart disease. Most people at 40 don't think of heart disease, but HIV-positive people have to start thinking about it.\" \nThe risk of heart disease in South Africa's HIV-positive population meant the trial was important, Ramjee said. Share Tweet SHARE YOUR OPINION If you have an opinion you would like to share on this article, please to the Times LIVE iLIVE team. In the mean time, click here to view the Times LIVE iLIVE section.", "external_links": [], "published": "2017-02-28T14:00:00.000+02:00", "crawled": "2017-02-28T07:12:39.188+02:00", "highlightTitle": ""}